However, to date, information regarding the clinicopathological significance, tumour immune status and the non-invasive assessment of 18F-FDG-uptake, which was regulated by the accumulation of HIF-1A and GLUT1 and EMT induction characterised by the epithelial marker suppression in OSCC, remains limited. The gene discussed is SLC2A1; the disease is neoplasm.